A very comprehensive review on current state of HCC screening, diagnosis and treatment.

www.jhep-reports.eu/article/S258...

#Liversky

@easlnews.bsky.social

Thrilled to share that I’ve joined NYU Langone as Medical Director of the Liver Cancer Program. Grateful for the opportunity to lead an incredible team focused on pushing the boundaries of liver cancer care and research. Big things ahead.

The figure shows the percentage of patients with fibrosis stage 2 or 3 who had resolution of steatohepatitis with no worsening of liver fibrosis (Panel A) and reduction in liver fibrosis with no worsening of steatohepatitis (Panel B) after 72 weeks, with the estimated difference expressed in percentage points.

In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM

#MedSky #EndoSky #GastroSky

Every year I feel so fortunate to be part of this #LiverCancer community with these amazing friends who are true leaders sharing a common goal!! Amongst the beautiful chaos that is life, it’s important to find your passion and your people 💚. That’s a wrap @hcclive.bsky.social

AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals Hepatitis B reactivation (HBVr) can occur due to a variety of immune-modulating exposures, including multiple drug classes and disease states. Antiviral prophylaxis can be effective in mitigating the ...

🚨 AGA New Guideline Alert Link🚨
▶️ AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
I’ll break down its FIVE recommendations over the next 12 posts 🧵 👇
#AGA #GI #HBV

www.gastrojournal.org/article/S001...

It me

Do conversations about prognosis (defined as "conversation with your hepatologist about the likely outcome of your liver disease over time") cause patients w/ cirrhosis to lose hope?

Simple answer: No

Work led by🌟@donlan_john in CGH @amergastroassn.bsky.social https://buff.ly/4i1R6OM #LiverSky

We are on our second starter pack for GI / Hepatology
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR

#medsky #GIsky #LiverSky

Ponni Perumalswami gave such a beautiful talk on management of alcohol-related liver disease at #TLM24 post-graduate course.